Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: Comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose

Journal of Nuclear Medicine

Volumn 49, Issue 5, 2008, Pages 837-844

  Rajendran, Joseph G ^a   Gopal, Ajay K ^b   Fisher, Darrel R ^c   Durack, Larry D ^a   Gooley, Ted A ^d   Press, Oliver W ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Internal dose; Non Hodgkin's lymphoma; Patient specific dosimetry; Radioimmunotherapy

Indexed keywords

TOSITUMOMAB I 131; IODINE 131 ANTI B1 ANTIBODY; IODINE-131 ANTI-B1 ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSE CALCULATION; DOSIMETRY; DRUG DISTRIBUTION; FEMALE; HUMAN; LIVER; LUNG; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; ORGAN SIZE; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; RADIOIMMUNOTHERAPY; RETROSPECTIVE STUDY; SCINTILLATION CAMERA; TREATMENT PLANNING; COHORT ANALYSIS; METHODOLOGY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY; WHOLE BODY COUNTING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; COHORT STUDIES; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; NEOPLASM, RESIDUAL; RADIATION DOSAGE; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; RECURRENCE; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; WHOLE-BODY COUNTING;

EID: 44149092900     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.043190     Document Type: Article

References (37)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16:2780-2795.
2. 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma. Semin Oncol. 2003;30:11-16.
3. 131I-Tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-449.
4. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934-2942.
5. Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood. 2002;99:3158-3162.
6. Nademanee A, Molina A, Dagis A, et al. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma. Clin Lymphoma. 2000;1:46-54.
7. Behr TM, Griesinger F, Riggert J, et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support: results of a pilot study. Cancer. 2002;94:1363-1372.
8. Eary JF, Press OW, Badger CC, et al. Imaging and treatment of B-cell lymphoma. J Nucl Med. 1990;31:1257-1268.
9. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000;18:1316-1323.
10. Kaminski MS, Fig LM, Zasadny KR, et al. Imaging, dosimetry and radioimmunotherapy with iodine-131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol. 1992;10:1696-1711.
11. DeNardo GL, Schlom J, Buchsbaum DJ, et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer. 2002;94:1332-1348.
12. 131I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes. J Nucl Med. 2004;45:1059-1064.
13. Fisher DR. Radiation dosimetry for radioimmunotherapy: an overview of current capabilities and limitations. Cancer. 1994;73:905-911.
14. Fowler JF. Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys. 1990;18:1261-1269.
15. Fisher DR. Assessments for high dose radionuclide therapy treatment planning. Radiat Prot Dosimetry. 2003;105:581-586.
16. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol. 1998;16:3270-3278.
17. Leichner PK, Akabani G, Colcher D, et al. Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. J Nucl Med. 1997;38:512-516.
18. 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation. J Nucl Med. 2002;43:1383-1390.
19. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med. 2002;32:148-155.
20. DeNardo GL, Juweid ME, White CA, Wiseman GA, DeNardo SJ. Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing. Crit Rev Oncol Hematol. 2001;39:203-218.
21. 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med. 2000;27:766-777.
22. Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med. 1998;39:14S-20S.
23. Eary JF, Press OW. High dose radioimmunotherapy in malignant lymphoma. Recent Results Cancer Res. 1996;141:177-182.
24. Fisher DR, Harty R. The microdosimetry of lymphocytes irradiated by alpha-particles. Int J Radiat Biol Relat Stud Phys Chem Med. 1982;41:315-324.
25. DeNardo DA, DeNardo GL, Yuan A, et al. Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies. J Nucl Med. 1996;37:1970-1975.
26. Eary JF, Pollard KR, Durack LD, et al. Post therapy imaging in high dose I-131 radioimmunotherapy patients. Med Phys. 1994;21:1157-1162.
27. Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculation. Revised ed. Reston, VA: Society of Nuclear Medicine; 1991.
28. Fisher DR. Internal dosimetry for systemic radiation therapy. Semin Radiat Oncol. 2000;10:123-132.
29. Williams LE, Liu A, Raubitschek AA, Wong JY. A method for patient-specific absorbed dose estimation for internal beta emitters. Clin Cancer Res. 1999;5:3015s-3019s.
30. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346:336-340.
31. Heymsfield SB, Fulenwider T, Nordlinger B, Barlow R, Sones P, Kutner M. Accurate measurement of liver, kidney, and spleen volume and mass by computerized axial tomography. Ann Intern Med. 1979;90:185-187.
32. Matthews DC, Appelbaum FR, Press OW, Eary JF, Bernstein ID. The use of radiolabeled antibodies in bone marrow transplantation for hematologic malignancies. Cancer Treat Res. 1997;77:121-139.
33. Wahl RL. The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab. Semin Oncol. 2003;30:31-38.
34. Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood. 2003;102:2351-2357.
35. Eary JF, Krohn KA, Press OW, Durack L, Bernstein ID. Importance of pretreatment radiation absorbed dose estimation for radioimmunotherapy of non-Hodgkin's lymphoma. Nucl Med Biol. 1997;24:635-638.
36. 131I. Cancer Res. 1991;51:5921-5928.
37. Eary JF, Appelbaum FR, Durack LD, et al. Preliminary validation of the opposing view method for quantitative gamma camera imaging. Med Phys. 1989;16:382-387.